Somalogic Inc
F:76X0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Somalogic Inc
Selling, General & Administrative
Somalogic Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Somalogic Inc
F:76X0
|
Selling, General & Administrative
-$156.6m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Selling, General & Administrative
-$8.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Danaher Corp
NYSE:DHR
|
Selling, General & Administrative
-$7.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-5%
|
|
|
Waters Corp
NYSE:WAT
|
Selling, General & Administrative
-$830.4m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Selling, General & Administrative
-$1.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Selling, General & Administrative
-$2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-8%
|
|
Somalogic Inc
Glance View
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in New York City, New York and currently employs 320 full-time employees. The company went IPO on 2021-02-23. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaSignal Tests, SomaScan Panels, and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. SomaSignal Tests are available as laboratory developed tests (LDT) for use in obtaining proteomics information from patients and monitoring patients’ physiological states, among others. SomaScan Panels consists of two categories: fixed panels and custom panels. The company offers drug development, analysis of clinical trial and new human biology insights.
See Also
What is Somalogic Inc's Selling, General & Administrative?
Selling, General & Administrative
-156.6m
USD
Based on the financial report for Dec 31, 2022, Somalogic Inc's Selling, General & Administrative amounts to -156.6m USD.
What is Somalogic Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 3Y
-67%
Over the last year, the Selling, General & Administrative growth was -101%. The average annual Selling, General & Administrative growth rates for Somalogic Inc have been -67% over the past three years .
